Related Experiment Videos
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease
1Department of Medicine and Center of Excellence on Aging, CeSI, University, School of Medicine, Chieti, Italy. ppatrignani@unich.it
Thrombosis Research
|November 1, 2003
Summary
Aspirin resistance, or failure to protect from clots, may stem from incomplete thromboxane A2 suppression due to COX-2, drug interactions, or altered COX-1. Other eicosanoids also contribute to this aspirin failure.
Area of Science:
- Cardiovascular Pharmacology
- Biochemistry
- Thrombosis Research
Background:
- Aspirin (acetylsalicylic acid) inhibits cyclooxygenase-1 (COX-1) for cardioprotection, but some patients show aspirin resistance.
- Aspirin resistance is linked to incomplete thromboxane A2 (TXA2) suppression, potentially due to COX-2 expression, drug interactions, or COX-1 variants.
Purpose of the Study:
- To investigate mechanisms of aspirin resistance in patients with unstable angina.
- To explore the role of enhanced eicosanoid biosynthesis in aspirin failure.
Main Methods:
- Assessed TXA2 biosynthesis in patients treated with low-dose aspirin.
- Investigated 8-iso-PGF2alpha and cysteinyl leukotrienes (cys-LTs) formation.
- Considered the use of selective COX-2 inhibitors, TP antagonists, and cys-LT inhibitors.
Main Results:
- Demonstrated enhanced TXA2 biosynthesis in a subset of aspirin-treated unstable angina patients.
- Observed increased formation of 8-iso-PGF2alpha and cys-LTs.
- Identified potential mechanisms for aspirin resistance beyond COX-1 inhibition.
Conclusions:
- Aspirin resistance may involve aspirin-insensitive eicosanoid pathways.
- Enhanced TXA2, 8-iso-PGF2alpha, and cys-LTs contribute to aspirin failure.
- Targeting these pathways may improve cardioprotection in resistant patients.